Fyodor is working to address the urgent medical needs of people in target emerging economies by matching novel biotechnologies to existing healthcare needs, and then developing and commercializing these technologies to meet those needs. Our complementary suite of diagnostic and biopharmaceutical products will enable the large scale detection and effective treatment of a variety of leading diseases that are endemic in rapidly emerging frontier markets, with initial focus on malaria.

To effectively position our products and better facilitate our market advantage, Fyodor intends to construct a world class biotechnology manufacturing facility in Nigeria, whose 145 million people account for 25% of all malaria cases in Africa.  Fyodor’s biotechnology center will galvanize biotechnology-based socio-economic development locally in the region and enhance its competitiveness in both the regional and global biotech marketplace. Additionally, it will strengthen Fyodor’s development and commercialization capabilities.